EMA's CHMP recommends EU marketing authorisation for Rasonque in metastatic pancreatic cancer

The EMA said its CHMP has recommended granting a marketing authorisation in the European Union for Rasonque (daraxonrasib) for metastatic pancreatic cancer.

Detected & updated continuously · Source: Nebula